top of page
  • Active, not recruiting

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

Updated: Feb 20

  • MagnetisMM-3

  • NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma


MagnetisMM-3

Relapsed & Refractory Multiple Myeloma

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb


Sponsor


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04649359

Official Title: MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY

First Posted : December 2, 2020


Click here for details on Clinicaltrials.gov


 

Elranatamab (Code C146860)

Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135

B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135

BCMA x CD3 Bispecific Antibody PF-06863135

BCMA-CD3 Bispecific Ab PF-06863135

Elranatamab

ELRANATAMAB

PF 06863135

PF-06863135

PF06863135

RN 613

RN-613

RN613


 

Nature Medicine

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

 

Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT04649359

Abstract#: 8006 - Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).

 

ABSTRACTS & PRESENTATIONS

2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting

2022 ASCO Annual Meeting - Oral Abstract Session

 

- Florida: Miami Cancer Institute

- Georgia: Emory University Atlanta

- Iowa: University of Iowa Iowa city

- Massachusetts: Massachusetts General Hospital Boston

- New Jersey: Hackensack University Medical Center

- New York: Roswell Park Cancer Institute Buffalo

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- Pennsylvania: Fox Chase Cancer Center Philadelphia

- Texas: Baylor University Medical Center Dallas

 

Locations

United States, California

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kentucky

United States, Louisiana

United States, Massachusetts

United States, New Jersey

United States, New York

United States, Pennsylvania

United States, South Carolina

United States, Texas


Canada, Alberta

Canada, Quebec


Europe

United Kingdom

France

Germany

Spain

Belgium

Poland

Asia

Japan

Australia, Victoria

 

RELATED POSTS


MagnetisMM-1

NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma - MagnetisMM-1


MAGNETISMM-2

NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2


MagnetisMM-4

NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4


MagnetisMM-5

NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5


MagnetisMM-7

NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7


MagnetisMM-8

NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8


MagnetisMM-9

NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9


NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)








Comentarios


Los comentarios se han desactivado.
Posts Archive
bottom of page